{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:44:03Z","timestamp":1787240643241,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF\u2010 019508"],"award-info":[{"award-number":["MJFF\u2010 019508"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["DYS\u201020\u201002"],"award-info":[{"award-number":["DYS\u201020\u201002"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Levodopa\u2010induced dyskinesia (LID) in Parkinson's disease (PD) is associated with \u2018false neurotransmitter\u2019 release of dopamine from serotonin (5\u2010HT) neurons. NLX\u2010112 is a first\u2010in\u2010class, highly selective 5\u2010HT\n                      <jats:sub>1A<\/jats:sub>\n                      receptor agonist which counteracts LIDs in experimental PD models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The primary objective was to evaluate the safety and tolerability of NLX\u2010112 compared with placebo in people with PD. The secondary objective was to assess the preliminary efficacy of NLX\u2010112 in reducing LID and its effects on PD symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants received NLX\u2010112 or placebo (2:1 ratio) alongside stable Parkinson's medications, with 22 participants completing the study. Dosing was up\u2010titrated over 28\u2009days to 2\u2009mg\/day (1\u2009mg twice daily), stabilized for 14\u2009days (to day 42), and down\u2010titrated for 14\u2009days. Efficacy was measured using the Unified Dyskinesia Rating Scale (UDysRS), Unified Parkinson's Disease Rating Scale (UPDRS), and Clinical Global Impression of Change (CGI\u2010C) following a levodopa challenge (150% of usual dose).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adverse events (AEs) were mainly central nervous system (CNS)\u2010related and mostly occurred during up\u2010titration, with no serious AEs in the NLX\u2010112 group. There were no treatment\u2010induced clinically significant changes in vital signs, electrocardiogram, or laboratory parameters. NLX\u2010112 reduced LID from baseline levels:\u00a0at day 42, UDysRS total score decreased by 6.3 points, whereas placebo group changes were not significant (\u22122.4). NLX\u2010112 also reduced parkinsonism from baseline values: UPDRS Part 3 scores decreased by 3.7 points, whereas placebo group changes were non\u2010significant (+0.1). In CGI\u2010C assessment, the NLX\u2010112 group showed greater improvement than the placebo group (53% vs. 29%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These results support further clinical investigation of NLX\u2010112 for treatment of PD LID. \u00a9 2025 Neurolixis SAS.\n                      <jats:italic>Movement Disorders<\/jats:italic>\n                      published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.30175","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T04:43:31Z","timestamp":1742186611000},"page":"1134-1142","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["<scp>NLX<\/scp>\n                    \u2010112 Randomized\n                    <scp>Phase 2A<\/scp>\n                    Trial: Safety, Tolerability, Anti\u2010Dyskinetic, and Anti\u2010Parkinsonian Efficacy"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-3802","authenticated-orcid":false,"given":"Per","family":"Svenningsson","sequence":"first","affiliation":[{"name":"ASC Torsplan  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund University, Sk\u00e5ne University Hospital  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3437-0267","authenticated-orcid":false,"given":"Filip","family":"Bergquist","sequence":"additional","affiliation":[{"name":"Sahlgrenska Hospital  Gothenburg Sweden"},{"name":"Department of Pharmacology University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Wirdefeldt","sequence":"additional","affiliation":[{"name":"Department of Neurology Karolinska University Hospital  Solna Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-7715","authenticated-orcid":false,"given":"Dag","family":"Nyholm","sequence":"additional","affiliation":[{"name":"Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Andr\u00e9asson","sequence":"additional","affiliation":[{"name":"ASC Torsplan  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-5746","authenticated-orcid":false,"given":"Ioanna","family":"Markaki","sequence":"additional","affiliation":[{"name":"ASC Torsplan  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders C.","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Neurology Karolinska University Hospital  Solna Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5ns","family":"Jergil","sequence":"additional","affiliation":[{"name":"Clinical Trial Consultants, AB  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jankosky","sequence":"additional","affiliation":[{"name":"Neurolixis Inc.  Park Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Varney","sequence":"additional","affiliation":[{"name":"Neurolixis Inc.  Park Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Herbrecht","sequence":"additional","affiliation":[{"name":"Neurolixis SAS  Castres France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Neurolixis Inc.  Park Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman\u2010Tancredi","sequence":"additional","affiliation":[{"name":"Neurolixis SAS  Castres France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-2012-120103"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60683-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.04.019"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)01281-8"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91511-3"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199902250-00034"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-023-00773-9"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)00922-9"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2020.00026"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2008.04.021"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06556.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711839105"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.4.376-a"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199402000-00008"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI71640"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20370"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu409"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29713"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12762"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107937"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107997"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.08.009"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.05.021"},{"key":"e_1_2_8_25_1","unstructured":"PaillardB Del FrariL BrunnerV Newman\u2010TancrediA VarneyM.A method for treating movement disorders with befiradol; WO2016005527A12016."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0071-3"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2196-4"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00249-0"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015298"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.036558"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26159"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-191841"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00429-018-1672-7"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06103-1"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524183113"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.21978"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2017.03.013"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2018.01.010"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2023.103497"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.30175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:53:10Z","timestamp":1760961190000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.30175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/mds.30175"],"URL":"https:\/\/doi.org\/10.1002\/mds.30175","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"2024-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}